Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)
- Registration Number
- NCT02499614
- Lead Sponsor
- Fondazione Ricerca Traslazionale
- Brief Summary
Phase II, two arms, parallel, non comparative study with crizotinib in patients with ROS 1 translocation or MET amplification or MET exon 14 mutation
- Detailed Description
This is a phase II, prospective, two arms, parallel, non comparative study with crizotinib in pretreated NSCLC patients with ROS1 translocation or MET amplification or MET exon 14 mutation (figure 1). Patients with locally advanced or metastatic NSCLC, pretreated with at least one previous chemotherapy line and with at least one measurable tumor lesion will be considered eligible for the trial. All potentially eligible patients will be evaluated for MET and ROS1 by FISH to detect MET amplification or ROS1 translocation. MET mutation will be assessed using direct sequencing or high sensitive methods. After evaluation of inclusion and exclusion criteria, and after signature of informed consent form, all MET amplified or MET exon 14 mutation or ROS1 translocated eligible patients will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 80
- Histologically confirmed diagnosis of NSCLC
- Availability of tumor tissue for ROS1 and MET analyses
- Patient positive for ROS1 translocation or MET amplification
- At least one radiological measurable disease according to RECIST criteria (Response Evaluation Criteria in Solid Tumors )
- At least 1 previous standard chemotherapy regimen
- Performance status 0-2 (ECOG)
- Patient compliance to trial procedures
- age ≥ 18 years
- Written informed consent
- Adequate BM function (ANC ≥ 1.5x109/L, Platelets ≥ 100x109/L, HgB > 9g/dl)
- Adequate liver function (bilirubin <G2, transaminases no more than 3xULN/<5xULN in present of liver metastases).
- Normal level of alkaline phosphatase and creatinine.
- If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method [intrauterine contraceptive device (IUD), birth control pills, or barrier device] during and for ninety(90) days after end of treatment.
- No tumor tissue available or patient negative for ROS1 translocation or MET amplification
- Absence of any measurable lesion
- For ROS1+ patients: Previous therapy with crizotinib or any anti-ALK agent
- For MET amplified patients: Evidence of MET amplification in tumor tissue collected in EGFR mutant patient at time of EGFR-TKI acquired resistance occurrence. An EGFR mutant patient is eligible if MET amplification is detected in a tumor specimen collected before starting an EGFR-TKI
- No previous chemotherapy
- Concomitant radiotherapy or chemotherapy.
- Previous radiotherapy on the target lesion(s). If all sites were included in radiotherapy fields patient is eligible only if there is evidence of progressive disease after completion of radiotherapy.
- Symptomatic brain metastases
- Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma of the skin
- Pregnancy or lactating
- Other serious illness or medical condition potentially interfering with the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Patients with MET amplification or MET exon 14 mutation Crizotinib Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal. Patients with ROS1 translocation Crizotinib Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
- Primary Outcome Measures
Name Time Method Response rate to crizotinib in patients with ROS1 translocation or MET amplification or MET exon 14 mutation From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months
- Secondary Outcome Measures
Name Time Method Progression-free survival (PFS) From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months Overall Survival (OS) From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months Toxicity analysis: Incidence of Grade 3-4 Grade Toxicity graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0 From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months Correlation with additional tumor biomarkers in tumor tissue or blood From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months Response according to different levels of ROS1 translocation or MET amplification (ratio >2.2 and <5 versus ratio ≥ 5) or MET exon 14 mutation From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months
Trial Locations
- Locations (26)
Ospedale per gli Infermi - Presidio Ospedaliero di Faenza- Unità Operativa di Oncologia Medica
🇮🇹Faenza, Ravenna, Italy
Ospedale Umberto I°- Unità Operativa di Oncologia
🇮🇹Lugo, Ravenna, Italy
IRCCS A.O.U. San Martino- IST- Istituto Nazionale per la Ricerca sul Cancro- U.O.S. Tumori Polmonari
🇮🇹Genova, Italy
Ospedale Versilia- Oncologia
🇮🇹Camaiore, Lucca, Italy
Istituto Oncologico Veneto IRCCS- UOS Oncologia Toracica UOC. Oncologia Medica 2
🇮🇹Padova, Italy
Osp. Civile SS. Annunziata- U.O.C di Oncologia Medica
🇮🇹Sassari, Italy
Policlinico 'G.B.Rossi' Borgo Roma - A.O.U. Integrata (Giampaolo Tortora)- Oncologia Medica
🇮🇹Verona, Italy
A. O. "Ospedale di Circolo" di Busto Arsizio- Struttura Complessa di Oncologia Medica
🇮🇹Saronno, Varese, Italy
Ospedale Campo di Marte- U.O.C. di Oncologia Medica
🇮🇹Lucca, Italy
Ospedale Santa Maria della Misericordia - Azienda Ospedaliera di Perugia
🇮🇹Perugia, Italy
Istituto Europeo di Oncologia - Divisione di Oncologia Toracica
🇮🇹Milano, Italy
A.O.U. Policlinico di Modena- Oncologia Ematologia e Malattie Apparato Respiratorio
🇮🇹Modena, Italy
Ospedale di Ravenna- Oncologia Medica
🇮🇹Ravenna, Italy
Casa di Cura La Maddalena- U.O. Oncologia medica
🇮🇹Palermo, Italy
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)- Oncologia Medica
🇮🇹Meldola, Forlì- Cesena, Italy
Sacro Cuore- Don Calabria Hospital- U.O.C. Oncologia Medica
🇮🇹Negrar, Verona, Italy
A.O.U. Careggi- S.C. Oncologia Medica 1
🇮🇹Firenze, Italy
Azienda Ospedaliera di Rilievo Nazionale "S.G. Moscati"- U.O. di Oncologia Medica
🇮🇹Avellino, Italy
Istituto Toscano Tumori Ospedale San Donato- U.O.C. di Oncologia Medica Dipartimento di Oncologia USL-8
🇮🇹Arezzo, Italy
IRCCS Istituto Tumori "Giovanni Paolo II"- U.O. Oncologia Medica
🇮🇹Bari, Italy
A.O.U. "Maggiore della Carità"- Dipartimento Oncologico
🇮🇹Novara, Italy
Ospedale Civile Livorno- U.O. Dipartimento di Oncologia Medica
🇮🇹Livorno, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale"- Oncologia Medica Dipartimento Toraco-Polmonare
🇮🇹Napoli, Italy
Ospedale "Infermi" Rimini- UU.OO. Oncologia ed Ematologia
🇮🇹Rimini, Italy
Azienda Ospedaliero Universitaria Pisana (AOUP)- Pneumo-Oncologia - Dipartimento Cardio-Toracico
🇮🇹Pisa, Italy
Azienda Ospedaliera Universitaria di Parma- Struttura Complessa di Oncologia Medica
🇮🇹Parma, Italy